<DOC>
	<DOCNO>NCT00717236</DOCNO>
	<brief_summary>This Phase IIIb multicenter study evaluate safety efficacy certolizumab pegol ( CZP ) administer patient moderate-to-severe rheumatoid arthritis .</brief_summary>
	<brief_title>Certolizumab Pegol Treatment Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description>The treatment period start 12-week , double-blind , placebo-controlled , randomized period follow open-label extension phase . In double-blind phase , eligible patient randomize ( 4:1 ratio ) receive either certolizumab pegol ( CZP ) Placebo include Week 10 . The randomization stratify accord three factor : concomitant use methotrexate ( MTX , Yes No ) , prior anti-tumor necrosis factor ( anti-TNF ) use ( Yes No ) , disease duration category ( &lt; 2 year â‰¥ 2 year ) . From Week 12 patient remain study receive open-label CZP minimum 16 additional week CZP commercially available .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Adult patient establish moderate severe rheumatoid arthritis All concomitant disease pathological condition could interfere impact assessment study treatment Previous clinical trial previous biological therapy could interfere result present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Chronic Arthritis</keyword>
</DOC>